Name: Anatara Lifesciences (ANR) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

ANR

Pharmaceuticals, Biotechnology & Life Sciences

Anatara Lifesciences

Short interest: 0.00%; −0.01 pp 30d; as of 14 Oct 2024
Reported shorts: 558
Shares on issue: 192.894M

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Anatara Lifesciences

Anatara Lifesciences Ltd focuses on developing non-antibiotic oral solutions targeting gastrointestinal diseases for both humans and animals. The company operates in the biotechnology sector and strives to harness novel therapeutic compositions to address significant unmet medical needs. Its strategic emphasis on non-antibiotic approaches positions it as an innovative player in the digestive health market.

Company profile →

Anatara Lifesciences (ASX:ANR) has 0.00% of its shares on issue reported as short positions as of 14 Oct 2024, or about 558 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.34% in May 2016. ANR is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads ANR today

Zanger BreakoutWatchScore 18rank 1344 of 1942
CAN SLIMNot a candidate
Minervini Trend TemplateNot a candidate
Crowded-Short BreakoutNot a candidate
Quality compoundersNot a candidate

Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

ANR fundamentals

In the year to 30 Jun 2026, Anatara Lifesciences (ASX:ANR) recorded revenue of A$0 and a net loss after tax of A$933.2K. A year earlier it recorded revenue of A$0 and a net loss after tax of A$2.0M. Figures are in AUD, the company's reporting currency; source: ASX (Markit), as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →